Research programme: parasitic disease therapeutics - Kainomyx
Latest Information Update: 28 Aug 2024
At a glance
- Originator Cytokinetics
- Developer Kainomyx
- Class Antimalarials; Antiparasitics; Small molecules
- Mechanism of Action Cytoskeletal protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria; Parasitic infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Malaria in USA
- 28 Aug 2024 No recent reports of development identified for preclinical development in Parasitic-infections in USA
- 13 Jul 2020 Kainomyx in-licenses selective cytoskeletal protein inhibitors from Cytokinetics for treatment of Parasitic infections